Sign up to access all valuation multiples
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
2003
n/a
LTM Revenue $474M
LTM EBITDA $168M
$4.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Betta Pharmaceuticals has a last 12-month revenue (LTM) of $474M and a last 12-month EBITDA of $168M.
In the most recent fiscal year, Betta Pharmaceuticals achieved revenue of $403M and an EBITDA of $113M.
Betta Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Betta Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $474M | XXX | $403M | XXX | XXX | XXX |
| Gross Profit | $395M | XXX | $328M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $168M | XXX | $113M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $88.0M | XXX | $69.4M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $83.2M | XXX | $56.1M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $164M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Betta Pharmaceuticals's stock price is CNY 71 (or $10).
Betta Pharmaceuticals has current market cap of CNY 29.7B (or $4.1B), and EV of CNY 31.5B (or $4.4B).
See Betta Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.4B | $4.1B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Betta Pharmaceuticals has market cap of $4.1B and EV of $4.4B.
Betta Pharmaceuticals's trades at 10.9x EV/Revenue multiple, and 38.9x EV/EBITDA.
Equity research analysts estimate Betta Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Betta Pharmaceuticals has a P/E ratio of 49.8x.
See valuation multiples for Betta Pharmaceuticals and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| EV (current) | $4.4B | XXX | $4.4B | XXX | XXX | XXX |
| EV/Revenue | 9.3x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBITDA | 26.1x | XXX | 38.9x | XXX | XXX | XXX |
| EV/EBIT | 49.9x | XXX | 63.2x | XXX | XXX | XXX |
| EV/Gross Profit | 11.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 49.8x | XXX | 73.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 377.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBetta Pharmaceuticals's last 12 month revenue growth is 21%
Betta Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Betta Pharmaceuticals's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Betta Pharmaceuticals's rule of X is 87% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Betta Pharmaceuticals and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 87% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Betta Pharmaceuticals acquired XXX companies to date.
Last acquisition by Betta Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Betta Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Betta Pharmaceuticals founded? | Betta Pharmaceuticals was founded in 2003. |
| Where is Betta Pharmaceuticals headquartered? | Betta Pharmaceuticals is headquartered in China. |
| Who is the CEO of Betta Pharmaceuticals? | Betta Pharmaceuticals's CEO is Mr. Lieming Ding. |
| Is Betta Pharmaceuticals publicy listed? | Yes, Betta Pharmaceuticals is a public company listed on SHE. |
| What is the stock symbol of Betta Pharmaceuticals? | Betta Pharmaceuticals trades under 300558 ticker. |
| When did Betta Pharmaceuticals go public? | Betta Pharmaceuticals went public in 2016. |
| Who are competitors of Betta Pharmaceuticals? | Similar companies to Betta Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Betta Pharmaceuticals? | Betta Pharmaceuticals's current market cap is $4.1B |
| What is the current revenue of Betta Pharmaceuticals? | Betta Pharmaceuticals's last 12 months revenue is $474M. |
| What is the current revenue growth of Betta Pharmaceuticals? | Betta Pharmaceuticals revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Betta Pharmaceuticals? | Current revenue multiple of Betta Pharmaceuticals is 9.3x. |
| Is Betta Pharmaceuticals profitable? | Yes, Betta Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Betta Pharmaceuticals? | Betta Pharmaceuticals's last 12 months EBITDA is $168M. |
| What is Betta Pharmaceuticals's EBITDA margin? | Betta Pharmaceuticals's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Betta Pharmaceuticals? | Current EBITDA multiple of Betta Pharmaceuticals is 26.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
